Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
about
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioUse of tumour-responsive T cells as cancer treatment.Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.Prospects for immunotherapy of malignant disease.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapyMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI aloneEarly administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMTCellular therapy following allogeneic stem-cell transplantation.Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibCurrent status of haploidentical stem cell transplantation for leukemia.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Post-transplant adoptive T-cell immunotherapy.New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplTargeting natural killer cells and natural killer T cells in cancer.A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantationOptimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature.
P2860
Q30558271-07357767-49F8-4431-9FE1-77E9D1C1741DQ33685495-B0DCE80A-AD5A-4B78-A06B-9DDB04B6A318Q33750829-783F179A-36FE-4E74-AFF2-9BA48A827639Q33770125-490EBBD6-B654-45CF-BA2C-048FB289E73DQ34065058-92F036ED-07D4-4496-89E9-C9089BB6DA2EQ34202277-50E25313-BD53-4441-BC16-771DEB4153CCQ34285656-F5CC32B4-D8E1-4C7C-8BA1-6FAC8526CF1AQ34473121-86A23C32-4049-4309-AD74-412B66A47583Q34792645-4635F6E5-322E-459F-9067-96C71F22E7DBQ35041705-AD20DF53-12F1-4013-B924-B0A93A089B44Q35605318-36BBBF8B-7431-4472-84EE-BB19661CEF32Q35633858-95B8EBBC-154A-406F-93F8-61CED9821F35Q35848323-5A7517D4-E988-4FEE-94CD-81CEFD8CD0E7Q35849776-34FC7128-FFB2-4BCD-A1E3-32440EDB3BF0Q35900929-7A75FBA5-097F-4823-B7F1-B629D40B7F69Q36007708-7290D1D9-A9D0-4F0A-8143-7EB75ACFF52CQ36036334-A6595830-3670-44D8-8D18-C56951AFC56CQ36612643-49304AB7-467E-43E6-9DA5-5DD03C12BD79Q37071112-85B9701C-619A-4E92-B982-508A14D4E2D5Q37088557-A1175CE0-28F9-455F-823C-41317CF9FCB1Q37242561-874472BA-FAAB-4D7D-A9EE-C94C03133FB2Q37268318-4D820987-C0F2-4743-B8A0-EE13A41F15EBQ37344050-7DDAF9DD-837A-43F6-BE15-74411DC07F87Q37445265-2BCF4451-AFB8-4DFF-8C72-BC62B57006EBQ37609957-49BC9285-B323-43B6-9508-EFA9B64082D6Q37995950-EA5478C8-59DD-4844-A8A0-10962B048DB7Q41273685-CFF3C630-44A8-4793-BCAD-0859DE3EF0BCQ41336256-763FD01A-F44E-4542-9EA4-7CEFEE8605EF
P2860
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Durability of responses follow ...... for chronic myeloid leukemia.
@en
Durability of responses follow ...... for chronic myeloid leukemia.
@nl
type
label
Durability of responses follow ...... for chronic myeloid leukemia.
@en
Durability of responses follow ...... for chronic myeloid leukemia.
@nl
prefLabel
Durability of responses follow ...... for chronic myeloid leukemia.
@en
Durability of responses follow ...... for chronic myeloid leukemia.
@nl
P2093
P921
P1433
P1476
Durability of responses follow ...... n for chronic myeloid leukemia
@en
P2093
Apperley JF
Craddock C
Cwynarski K
Goldman JM
Olavarria E
P304
P407
P577
2000-10-01T00:00:00Z